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Upon fusion of multivesicular bodies (MVBs) with the plasma membrane, intraluminal vesicles
(ILVs) are released into the extracellular space as exosomes. Since the lipid composition of the exo-
somal membrane resembles that of raft microdomains, the inward budding process involves the
raft-like region of the MVB limiting membrane. Although published research suggests that cellular
RNAs may be selectively sorted into exosomes, the molecular mechanisms remain elusive. In this
review, we suggest that there is a continuous interaction of cellular RNAs with the outer (cytoplas-
mic) surface of MVBs and that the selection for incorporation of these RNAs into ILVs is based on
their afﬁnity to the raft-like region in the outer layer of the MVB membrane.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
1.1. Types of extracellular vesicles
There are several types of extracellular vesicles, including
exosomes, microvesicles, and apoptotic bodies. Exosomes are
nanovesicles (50–100 nm in diameter) that originate from the
endosome and are released from cells when multivesicular bodies
(MVBs) containing intraluminal vesicles (ILVs) fuse with the
plasma membrane. Microvesicles (also known as ectosomes or
shedding vesicles) are larger than exosomes (0.1–1 lm in diame-
ter) and are released from cells through blebbing (budding out)
and ﬁssion of the plasma membrane. Apoptotic bodies are the lar-
gest type of extracellular vesicles (0.5–2 lm in diameter) and are
shed from cells during apoptosis [1,2].
Exosomes are the most studied type of extracellular vesicles.
They are secreted by multiple cell types, including stem cells,
endothelial cells, smooth muscle cells, neuronal cells, and tumor
cells, and are detected in most bodily ﬂuids, including blood, urine,
saliva, semen, breast milk, cerebrospinal ﬂuid, and ascites [3,4].
Exosomes can functionally transfer speciﬁc sets of RNAs from par-
ent cells to recipient cells under physiological and pathologicalconditions. RNA in exosomes is protected from RNase degradation
and is stable under various temperature and pH conditions [5].
1.2. Composition of exosomes
In mammalian cells, exosomes are characterized by speciﬁc sets
of lipids, proteins and RNAs. The lipid composition of the
exosomal membrane resembles that of raft microdomains,
with enrichment in sphingomyelin, cholesterol, glycosphin-
golipids, ceramide, phosphatidylserine, lyso-phosphatidylcholine,
lyso-phosphatidylethanolamine and phosphatidylcholine with
short saturated fatty acids (14:0, 16:0) [6–9]. Several classes of
proteins are considered exosome makers, including members of
the Endosomal Sorting Complex Required for Transport (ESCRT)
machinery (Alix, TSG101), heat-shock proteins (HSP 90/70) [10],
and transmembrane proteins called tetraspanins [11] which may
play a role in exosome sorting of receptors and other proteins
[12]. Some proteins can be also packaged into exosomes via their
association with lipid raft domains of the exosomal membrane
[13]. In addition to a common set of proteins, exosomes carry cell
type-speciﬁc proteins. For example, exosomes can transfer tumor
antigens from tumor cells to dendritic cells [14]. Exosomes isolated
from cells infected with various intracellular pathogens have been
shown to contain microbial components and can promote antigen
presentation and macrophage activation [15]. Cells can also release
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in association with exosomes.
Exosomes carry a distinctive repertoire of microRNAs (miRNAs),
other small non-coding RNAs (piRNA, snRNA, snoRNA, scaRNA, Y
RNA), natural antisense RNAs, tRNAs and their fragments, mRNAs
and their fragments, rRNAs, and long non-coding RNAs [19–23].
RNA proﬁle of exosomes often does not mirror the one of parent
cells, suggesting that RNA packaging into exosomes is a selective
process [1,2]. Because similar miRNA subsets are found in vesicles
secreted by a variety of cell types, a common mechanism for selec-
tive miRNA export may exist [2]. Although such a common mech-
anism is unknown, some progress has been made recently
whereby exosomal miRNA have been shown to be selected by pro-
teins, target mRNAs, or post-transcriptional modiﬁcations [24–26].
1.3. Functions of exosomal RNAs
Numerous reports suggest that exosomal RNAs can be used as
diagnostic biomarkers. For instance, miRNA signatures of
tumor-derived exosomes show promise as potential circulating
diagnostic biomarkers in ovarian cancer [27], prostate cancer
[28], and glioblastoma [21]. Moreover, miRNAs are exported via
exosomes from the human placental syncytiotrophoblast into
maternal circulation and therefore circulating miRNAs can serve
as diagnostic biomarkers in pregnancy disorders [29]. Circulating
miRNAs can also serve as biomarkers of liver damage and
inﬂammation [30], as well as atherosclerotic and cardiovascular
diseases [5,31]. In addition, exosomes released during prion
infection of neuronal cells have a distinct miRNA signature that
can be utilized for diagnosis and understanding of pathogenic
mechanisms [32].
Exosomal RNAs are not only stable and accessible biomarkers,
but they can be functionally transferred from parent cells to recip-
ient cells [19]. There are multiple studies describing various roles
of exosomal RNAs in cancer. For instance, mRNAs released in exo-
somes by glioblastoma cells are translated by recipient brain
microvascular endothelial cells [33]. Exosomes secreted by macro-
phages can deliver miRNAs into breast cancer cells to promote
invasion [34]. Exosomes secreted by human colorectal cancer cells
contain mRNAs, miRNAs and natural antisense RNAs that can be
transferred into the human hepatoma and lung cancer cell lines
[35]. Interestingly, breast cancer cells secrete exosomes with speci-
ﬁc capacity for cell-independent miRNA biogenesis, while normal
cell-derived exosomes lack this ability; these cancer exosomes
stimulate non-tumorigenic epithelial cells to form tumors by alter-
ing their transcriptome [36].
Although exosome secretion appears to be enhanced in tumors,
exosomal RNA transfer also occurs in physiological settings, espe-
cially between immune cells. MiRNAs transferred in exosomes
from T cells to antigen-presenting cells at immune synapses were
shown to be able to modulate gene expression in recipient cells
[37]. Similarly, the transfer of miRNAs between mouse dendritic
cells via exosomes was found to be functional, because they
repressed target mRNAs [38]. It was also demonstrated that
mRNAs, miRNAs, and cytokines carried by dendritic cell-derived
exosomes interact with and inﬂuence immune cells [39].
Exosomes secreted by nematode parasites transfer small RNAs to
mammalian cells and modulate innate immunity [40].
Cardiovascular exosomes released from a damaged or diseased
heart could be intercellular communicators and carry signaling
molecules to activate distant sites such as bone marrow [4].
Recent studies also demonstrate the critical role of exosomal
RNA uptake in nerve regeneration, synaptic function, and behavior
[42]. In addition, functional delivery of viral miRNAs via exosomes
has been demonstrated [41].2. Cellular processes leading to RNA loading into exosomes
2.1. MiRNA pathways
The majority of mammalian miRNA genes reside within introns
of protein-encoding and non-coding genes [43]. Most miRNAs are
transcribed as long primary miRNAs (pri-miRNAs) by RNA poly-
merase II and undergo sequential processing by RNase III enzymes
Drosha and Dicer to produce 19–24 nucleotide mature miRNA
duplexes (Fig. 1) [44]. Dicer then transfers the duplex to one of four
Argonaute (Ago) proteins. The guide strand of the duplex usually
starts with a 50-U, is A/G rich, and is preferentially loaded into
Ago to regulate expression of target mRNAs. The passenger strand
of the duplex frequently starts with a 50-C, is U/C rich, and is
thought to be degraded. However, expression proﬁling shows that
in some tissues both strands can be equally abundant [44].
Alternative Drosha-independent miRNA processing pathways have
also been described, including mirtrons, and snoRNA- and
tRNA-derived miRNAs.
It is possible that while one miRNA strand is loaded by Ago for
mRNA binding and subsequent repression, the other miRNA strand
is transported by RNA-binding proteins (RBPs) towards MVBs for
secretion in exosomes, or towards the plasma membrane for secre-
tion in microvesicles. Interestingly, evaluation of the miRNA con-
tent of cardiac ﬁbroblast-derived exosomes revealed a relatively
high abundance of many miRNA passenger strands [45]. Ago2 is
generally absent from exosomes suggesting that exosomal
miRNAs are protected from degradation and/or sorted by other
RBPs [26].
2.2. Endosomal vesicle pathways
Mammalian cells take up solutes, nutrients, ligands, and com-
ponents of the plasma membrane via multiple endocytic pathways,
all of which trafﬁc via early endosomes (Fig. 1) [46]. During endo-
some maturation into late endosomes, inward budding from the
limiting membrane of the endosome leads to the formation of
MVBs containing ILVs. During this process, some MVBs undergo
retrograde transport to the trans-Golgi network (TGN), some are
directed to lysosomes for cargo degradation, and some move along
microtubules to fuse with the plasma membrane to release their
ILVs into the extracellular space as exosomes [47,48].
MVBs appear in ultrathin sections as spherical organelles char-
acterized by a single outer (limiting) membrane that encloses a
variable number of small spherical or ellipsoidal ILVs that are
heterogeneous in size (typically 40–100 nm in diameter) [49].
Exosome diameter is equivalent to that of the ILVs fromwhich they
originate [48]. MVBs typically have a diameter of 250–1000 nm
and contain at least two and up to dozens of ILVs within the
membrane-enclosed lumen [49].
During MVB formation, cytosolic RNAs are taken up into ILVs
undergoing inward budding from the limiting membrane.
Because ILVs become exosomes, we designate this budding-in pro-
cess as ‘‘RNA loading into exosomes’’. Below we propose selective
lipid-mediated mechanisms of RNA loading into exosomes.
3. Lipid-mediated RNA loading into exosomes
Exosomes are enriched in cholesterol, sphingomyelin, glycosph-
ingolipids and phosphatidylcholine with saturated fatty acids
because ILVs are created during the spontaneous inward budding
of the raft-like region of the MVB limiting membrane (Fig. 2). We
propose that the ﬁrst step of RNA loading into exosomes occurs
before this budding process, when an RNA molecule binds to this
raft-like region. RNA residence on membranes is determined by
Fig. 1. Exosome biogenesis in the parent cell and exosomal uptake by the recipient cell. MiRNA/mRNA pathways (blue arrows) and vesicular pathways (orange arrows) meet
at the cytoplasmic site of the endosomal limiting membrane where some RNA molecules bind to the limiting membrane. MiRNA strands are transported by RNA-binding
proteins (RBPs) towards multivesicular bodies (MVBs) for exosome loading, or towards the plasma membrane for secretion. During maturation, endosomes can be
transported to the trans-Golgi network (TGN), directed to lysosomes for degradation, or move along microtubules to fuse with plasma membrane thus releasing their
intraluminal vesicles (ILVs) as exosomes into the extracellular space. Exosomes from the parent cell can interact with the recipient cell through juxtacrine signaling,
endocytosis or fusion. Microvesicles are released from the parent cell into the extracellular space through outward budding of the plasma membrane.
Fig. 2. Binding of RNAs to the raft-like region of the cytoplasmic leaﬂet of the MVB limiting membrane. RNA, transported by a RNA-binding proteins (RBPs), interacts with the
cytoplasmic surface of the MVB limiting membrane. RNAs with the highest afﬁnity to the raft-like region are retained at the membrane. The afﬁnity of an RNA molecule to the
raft-like region is determined by binding motifs in the RNA sequence as well as by the RNA hydrophobic modiﬁcations. The presence of ceramide molecules (having an
inverted cone shape) in the cytoplasmic leaﬂet of the membrane, and both lyso-phospholipid and glycosphingolipid molecules (both having a cone shape) in the lumenal
leaﬂet induces spontaneous budding-in process from the raft-like region (see the rectangular insert), producing intraluminal vesicles (ILVs) that will become exosomes upon
multivesicular body (MVB) fusion with the plasma membrane.
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(particularly lipid rafts), and sphingosine at a physiological concen-
tration in rafted membranes [50,51]. Speciﬁc nucleotide sequences
demonstrate enhanced afﬁnity to phospholipid bilayers [52–55]. In
fact, by combining such preselected membrane afﬁnity RNA motifs
with an amino acid binding RNA motif, a passive membrane trans-
porter speciﬁc for the amino acid tryptophan has been constructed
and characterized [56].
We suggest that there is a continuous interaction of cellular
RNAs with the outer (cytoplasmic) surface of the MVB limiting
membrane, and also a continuous budding-in process at the MVBlimiting membrane. The selection for incorporation of these RNAs
into ILVs is based on the afﬁnity of RNAs to the raft-like regions
in the outer layer of the MVB membrane. However, the
budding-in process takes place independently of RNA binding.
3.1. Formation of the raft-like region in the cytoplasmic leaﬂet of the
MVB limiting membrane
Since MVB is one of the end-products of the endosomal path-
way, it contains plasma membrane lipids (e.g. lipids speciﬁc for
membrane rafts) and proteins (e.g. neutral sphingomyelinase 2,
1394 T. Janas et al. / FEBS Letters 589 (2015) 1391–1398nSMase 2). nSMase 2, which breaks down sphingomyelin into
phosphocholine and ceramide, is palmitoylated on multiple cys-
teine residues in the catalytic region enabling its localization at
the inner leaﬂet of the plasma membrane [57]. The inner leaﬂet
of the plasma membrane is topologically equivalent to the cyto-
plasmic (external) leaﬂet of the MVB limiting membrane. Thus
nSMase produces ceramide molecules embedded in the cytoplas-
mic leaﬂet of the MVB limiting membrane. nSMase 2 interacts
speciﬁcally and directly with phosphatidylserine and phosphatidic
acid and the enzymatic activity of nSMase 2 is dependent on these
anionic phospholipids [58]. Raft-like regions and exosomes are
enriched in these anionic phospholipids [7,9], which in turn attract
and activate nSMase 2 resulting in ceramide generation at ILV bud-
ding sites. Ceramide is subject to a number of metabolic processes,
including conversion to sphingosine and sphingosine 1-phosphate
(S1P) by ceramidase and sphingosine kinase [59]. The continuous
activation of sphingosine 1-phosphate receptors on MVBs medi-
ates maturation of MVBs and regulates tetraspanin sorting into
ILVs [59].
Ceramide has a unique biophysical property in that it can
self-associate through hydrogen bonding, providing the driving
force that results in the coalescence of microscopic rafts into a
large-membrane macrodomain [60]. This structure can serve as a
platform for the ILV budding-in process. Ceramide molecules pref-
erentially locate in the raft-like regions of the membrane [61].
Ceramide-promoted heterogeneity and clustering of raft domains
provides strong support for ceramide-induced formation of func-
tional platforms in cell membranes [62]. Sphingomyelinase causes
membrane microdomain formation and domain clustering in the
giant liposome membrane composed of phosphatidylcholine and
sphingomyelin, and subsequent shedding of small vesicles from
the membrane into the interior of the giant liposome [63].
3.2. Lipid-induced inward budding of the raft-like region of the MVB
limiting membrane
Puriﬁed exosomes are enriched in ceramide, and the release of
exosomes is reduced after the inhibition of nSMases [64]. Indeed,
ceramide triggers secretion of exosomes and some exosomal
miRNAs are released through a ceramide-dependent secretory
machinery and independent on the ESCRT system in mammalian
cells [65]. An alternative ESCRT-independent pathway for sorting
cargo into MVBs seems to depend on raft-based microdomains
for the lateral segregation of cargo within the endosomal mem-
brane [64].
Exosomes are also enriched in lyso-phosphatidylcholine
(lyso-PC) and lyso-phosphatidylethanolamine (lyso-PE) [7,8]
which may be important for the budding process. Group V secre-
tory phospholipase A2 (sPLA2-V) is present in the Golgi apparatus
and in the recycling endosomes [66] and therefore it can generate
lyso-PC and lyso-PE within the lumenal leaﬂet of the MVB limiting
membrane. One of the main components of lipid rafts is dipalmi
toylphosphatidylcholine [67]; in MVB limiting membrane it serves
as a substrate for phospholipase A2 and also can play a stabiliza-
tion role during the formation of a raft-like region within this
membrane. However, it is not involved in the budding process
due to its cylindrical molecular shape (the hydrophilic–hydropho-
bic balance close to 1).
Glycosphingolipids (including gangliosides) are also enriched in
the exosomal membranes. Since their original localization is at the
external surface of the plasma membrane, they have an inward ori-
entation in the endosomal membrane, and hence they are localized
at the external surface of the ILVs. Because of their large hydrophi-
lic headgroups and small differences in oligosaccharide structures,
glycosphingolipids are good candidates to stabilize membrane
lipid domains and subdomains with positive curvature [68]. Dueto their membrane orientation (towards the lumen of the
MVB), glycosphingolipids are likely not involved in the
interaction of RNAs with the MVB limiting membrane at the cyto-
plasmic site.
The cone-shaped structure of ceramide located in the raft-like
region of the outer (cytoplasmic) leaﬂet of the limiting membrane
and the inverted cone-shaped structure of lyso-phospholipids and
glycosphingolipids in the inner (lumenal) leaﬂet of this membrane
can induce a membrane curvature by creating an area difference
between the membrane leaﬂets (Fig. 2, the insert). This can lead
to a spontaneous budding-in process from the MVB limiting mem-
brane thus creating ILVs inside the MVB. The topology of the bud-
ding region (and hence the topology of an ILV) corresponds to the
topology of the plasma membrane; its much bigger curvature can
be achieved by the action of nSMase 2 at the cytoplasmic side and
sPLA2-V at the lumenal side of the MVB limiting membrane. Since
the surface of a budding vesicle (the raft-like region) is much big-
ger than the surface of its border region (having an opposite curva-
ture – see Fig. 2, the insert), the driving force for the budding
process most likely comes mainly from the raft-like region, not
from its border region. The opposite curvature of the border region
requires cone-shaped lipids at the cytoplasmic leaﬂet of the border
region. These cone-shaped lipids can arrive to the border region
from the area of the MVB limiting membrane outside the
raft-like region, where lyso-phospholipids can be created from
phospholipids by the action of cytosolic phospholipases [66].
Speciﬁc membrane proteins in the MVB limiting membrane can
also preferentially locate in the raft-like region [13]. It was sug-
gested that these raft domains may represent weak points on the
membrane surface, prone to outward bending or budding [13].
Bismonoacylglycerophoshate (BMP, LBPA) is not enriched in the
exosomal membranes [9]. BMP is involved in the processes related
to the degradation pathway not secretion pathway (Fig. 1), and it is
enriched in late endosomes and lysosomes [9,46,69].
3.3. Binding of RNAs to the raft-like region of the MVB limiting
membrane
In contrast to proteins, which can be sorted in an
ubiquitin-dependent manner into MVBs by ESCRT [70], RNA sort-
ing in mammalian cells appears independent of ESCRT and depen-
dent on ceramide [65]. In addition, miRNA sorting into exosomes
may be a passive mechanism to dispose of miRNAs that are in
excess of their cellular targets [25]. Because the raft-like region
contains ceramide molecules [61], we suggest that selective sort-
ing of RNAs depends on differential afﬁnity of RNA motifs to the
raft-like region of the cytoplasmic surface of the MVB limiting
membrane. This differential afﬁnity of RNAs to the raft-like region
has been shown previously [71]. RNAs with a speciﬁc secondary
structure bind to rafted (liquid-ordered) domains in sphingomye
lin–cholesterol–phosphatidylcholine vesicles [71] that resemble
liquid-ordered lipid phase of exosomal membranes [72].
Randomly structured RNA sequences have 20-fold lower afﬁnity
to the raft domains. In addition, speciﬁc nucleotide sequences are
required for enhanced afﬁnity to phospholipid bilayers [51,52],
and domains with membrane afﬁnity are not observed in random
RNA sequences. Similarly, exosomes secreted by human
cells transport mRNA fragments that are enriched in the
30-untranslated regions which contain sequence elements that
can determine subcellular localization of mRNAs [20].
The presence of sphingosine increases afﬁnity of tRNA to mem-
brane rafts [50]. Since ceramide in the MVB limiting membrane is
converted to sphingosine through the action of ceramidase [59]
and ceramide is produced in the raft-like region, sphingosine mole-
cules in the limiting membrane likely increase the afﬁnity of RNAs
to this membrane.
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both miRNA (the EXOmotif) [24] and mRNA [73]. Interestingly,
ten EXOmotifs (three GCCG, two UGAC, two UCCG, GGAC, GGCG,
UGCC) are present in the raft-binding sequence RNA 67–2 [71]:
GGGACGACGAUGACACGAUACUUUGUCGGCCGAACUCGCUGCUCC-
GAUCCGGCGAGAUCGCAGGGUGUUGCUAUUCGCGUGCCGUGUGC-
AUACGCCGAUCACAUGACCA [71]. Another subset of eleven
EXOmotifs (three GCCG, two UGAC, two UGCC, GGAC, GGCG,
CCCG, GGCC,) is found in another raft-binding sequence, RNA 10
[71]: GGGACGACGAUGACACGAUACUUUGUCGGCCGAACUCGCU-
GUUUAACUGCCCGGCGAGAUCGCAGGGUGUUGUGCUAUUCGCG-
UGCCGUGUGCAUACGCCGAUCACAUGACCA. RNA 67–2 and RNA 10
have been shown to have the strongest afﬁnity to the raft-like
region among the tested sequences [71].
We suggest that miRNAs are delivered to the raft-like region by
RBPs. Indeed, sequence-dependent miRNA association with
hnRNPA2B1 promotes their exosomal release [24]. Interestingly,
hnRNPA2B1 has an afﬁnity to the ceramide-rich membrane regions
[24]. Therefore, this protein can bind to raft-like regions in the
MVB limiting membrane and can be found in exosomes indepen-
dently of miRNAs. In contrast, Ago2 is generally absent from exo-
somes suggesting that miRNAs are secreted in exosomes
independently of the canonical miRNA machinery [26]. Since
miRNAs are expressed in a 13-fold excess relative to Agos in
HeLa cells [74], there is a surplus of miRNAs available for binding
to the raft-like region of MVBs.
It has been suggested that miRNAs which are bound to Ago but
are not interacting with target mRNAs are susceptible to degrada-
tion, whereas miRNAs that are interacting with target mRNAs are
protected [44]. We propose that the raft-like region of the MVB
can also function as a ‘‘target’’ for miRNAs. Therefore binding of
miRNAs either to mRNAs or to the raft-like region of MVBs protects
miRNAs from degradation independently of Ago. The relativelyFig. 3. Incorporation of RNA molecules into ILVs through the budding-in process. There
(MVB) limiting membrane. If there is an RNA molecule with high afﬁnity to the budding
then released into the extracellular space within this vesicle. Most of the budding-in eve
resembles pH of the cytoplasm (pH 7.4) whereas pH of the MVB lumen is lower (pH 5.5high abundance of many miRNA passenger strands in exosomes
[45] may result from this protective property of the raft-like
region.
There is another RNA property, besides the membrane binding
motif, which can affect the afﬁnity of an RNA molecule to the
membrane: its hydrophobic modiﬁcation. Some mammalian
miRNAs can be methylated [75] and tRNAs can have several
hydrophobic modiﬁcations, including isopentenylation which
increases tRNASec afﬁnity to the raft-like region of the membrane
[50]. Regulatory small RNAs with miRNA-like features that are
derived from cleavage of tRNASec are likely hydrophobically modi-
ﬁed because some reported reads overlap with the isopentenylated
nucleotide 37 [76]. Seminal exosomes contain a substantial
amount of tRNA fragments enriched for 50-ends (18–19 or 30–34
nucleotides in length), and such tRNA fragments repress transla-
tion [22]. Moreover, a recent report indicates that breast
cancer-speciﬁc miRNA signature unique to extracellular vesicles
includes ‘‘microRNA-like’’ tRNA fragments [77]. In addition, we
have found that the sequence of the anticodon arm loop CUUCAA
containing both the anticodon UCA and adenosine 37 (which, in
human tRNASec, is modiﬁed by the hydrophobic 5-carbon isoprene
chain) is also present in human miRNAs: miR-133a, miR-133b,
miR-4802, miR-676, miR-6839, and miR-6855. Interestingly,
miR-133a is secreted in exosomes from stimulated cardiomy-
oblasts and its circulating levels are increased in patients with car-
diovascular diseases [78], while miR-133b is functionally
transferred in exosomes from multipotent mesenchymal stromal
cells to astrocytes and neurons, which promotes recovery after
stroke [79,80].
Quantitative and stoichiometric analysis of the miRNA content
of exosomes revealed that there was far less than one molecule
of a given miRNA per exosome [81]. Even for the most abundant
miRNAs in exosome preparations, the ratio is one miRNA molecule
per 10 exosomes. On average, over 100 exosomes would need to beis a continuous and spontaneous budding-in process from the multivesicular body
-in raft-like region, it becomes encapsulated into the intraluminal vesicle (ILV) and
nts occur without any RNA attached to this membrane region. pH of the ILV lumen
).
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there is an average 0.00825 miRNAmolecules per exosome [81], on
average only one miRNA is incorporated per 120 (5  24)
ILVs/exosomes. One MVB contains an average of 24 ILVs [49] and
thus ﬁve MVBs need to fuse with the plasma membrane to release
one miRNA on average. Based on our model, the probability of
binding two RNAs to the same raft-like region is smaller than the
probability of binding only one molecule, and we can predict the
low-occupancy/low-miRNA concentration distribution in contrast
to the previously predicted a low-occupancy/high-miRNA concen-
tration distribution [81]. A continuous budding-in of the MVB lim-
iting membrane sometimes encloses an RNA molecule; it happens
only if the RNA molecule has been bound to the raft-like region of
the membrane (Fig. 3). Since the mean occupancy of miRNAs in
exosomes is 0.01 miRNA molecules per exosome [81] and the
percentage of miRNAs in total exosomal RNA is usually 10–40%
[23], there are more ‘‘empty’’ exosomes (without any RNA mole-
cule inside) than occupied exosomes (containing at least one
RNA molecule).
In summary, in our model the exosome sorting process (i.e. the
binding of cellular RNAs to the MVB limiting membrane, and the
subsequent internalization via ILVs) depends on: (1) the presence
of a lipid-bilayer binding motif within the RNA sequence; (2)
RNA hydrophobic modiﬁcations; (3) RNA concentration in cyto-
plasm; and (4) the presence of raft-like regions, enriched in speciﬁc
lipids, in the MVB limiting membrane.
The raft-dependent mechanism of exosome loading can also be
applied in the case of water-soluble proteins and membrane
peripheral proteins. Their ability to bind to the ordered region of
the lipid bilayer of the MVB limiting membrane can lead to their
entrapment inside exosomes. In the case of membrane integral
proteins, they are ﬁrst incorporated into the MVB limiting mem-
brane through a fusion process of membrane vesicles (originating
from the endoplasmic reticulum or Golgi). If they have an afﬁnity
to the raft-like region of the MVB limiting membrane, they accu-
mulate in the budding-in region of this membrane and thus are
secreted in the exosomal membrane.
4. What happens after exosome loading?
After inward budding of ILVs, the MVB moves along micro-
tubules and its limiting membrane fuses with the plasma mem-
brane at the cytoplasmic site thus releasing ILVs into the
extracellular space as exosomes [47,48]. The docking and fusion
of the MVB with the plasma membrane requires the cytoskeleton
(actin and microtubules), associated molecular motors (kinesins
and myosins), molecular switches (small GTPases), and the fusion
machinery (SNAREs and tethering factors) [48].
Circulating exosomes can be taken up by recipient cells by at
least three different mechanisms. First, the exosomal membrane
can fuse with the plasma membrane of the recipient cell at the
extracytoplasmic site thus releasing RNAs and proteins into the
cytoplasm of the recipient cell and incorporating exosomal mem-
brane and transmembrane proteins into the plasma membrane of
the recipient cell [38]. Second, exosomes can be internalized
into the recipient cell by endocytosis [82], including
clathrin-mediated endocytosis [83], caveolin-dependent endocyto-
sis [84], lipid rafts-mediated endocytosis [85], phagocytosis [86],
and micropinocytosis [87,88]. When endocytosed, exosomes may
subsequently fuse with the endosomal limiting membrane or be
targeted to lysosomes for degradation [48]. Third, after binding
to recipient cells, exosomes may remain stably associated with
the plasma membrane leading to activation of signaling pathways
through interaction between exosome ligands (e.g. EGFR ligands
[89], TNF superfamily ligands [90], and sialoglycoproteins [91])and cell-surface receptors. Stable and persistent cell surface expo-
sure can be expected particularly on cells that display little if any
endocytic activity [48].
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